Global Organoid Biobank Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Organoid Biobank Market Research Report 2024
Organoids refer to three-dimensional tissue structures constructed in vitro through cell engineering, tissue engineering or stem cell technology based on internal organs.
According to MRAResearch’s new survey, global Organoid Biobank market is projected to reach US$ 390.4 million in 2033, increasing from US$ 121 million in 2022, with the CAGR of 18.5% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Organoid Biobank market research.
The organoid biobank market is a growing field that encompasses the collection, storage, and distribution of human organoid models and biological samples required for a variety of medical and biological research. Key drivers of this market include increased demand for medical research, advances in organ transplantation and drug testing, developments in biotechnology, and the rise of personalized medicine. These biobanks provide researchers and pharmaceutical companies with important resources for disease research, drug screening, and personalized medicine, and therefore have huge potential and market opportunities in the fields of medicine and life sciences.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Organoid Biobank market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
FRANKFURT CANCER INSTITUTE
Merck
Crown Bioscience
HUB Organoids
Cancer Research UK Convergence Science Centre
Thermo Fisher Scientific
Corning
STEMCELL Technologies
Lonza
Prellis Biologics
Amsbio
Cellesce
DefiniGEN
3Dnamics Inc.
Organoid Therapeutics
InSphero
AIVITA Biomedical
JangoBio
Segment by Type
Tissue Derived Organoids
Pluripotent Stem Cell-derived Organoids
Biopharmaceutical Companies
Contract Research Organizations
Academics and Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Organoid Biobank report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Organoid Biobank market is projected to reach US$ 390.4 million in 2033, increasing from US$ 121 million in 2022, with the CAGR of 18.5% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Organoid Biobank market research.
The organoid biobank market is a growing field that encompasses the collection, storage, and distribution of human organoid models and biological samples required for a variety of medical and biological research. Key drivers of this market include increased demand for medical research, advances in organ transplantation and drug testing, developments in biotechnology, and the rise of personalized medicine. These biobanks provide researchers and pharmaceutical companies with important resources for disease research, drug screening, and personalized medicine, and therefore have huge potential and market opportunities in the fields of medicine and life sciences.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Organoid Biobank market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
FRANKFURT CANCER INSTITUTE
Merck
Crown Bioscience
HUB Organoids
Cancer Research UK Convergence Science Centre
Thermo Fisher Scientific
Corning
STEMCELL Technologies
Lonza
Prellis Biologics
Amsbio
Cellesce
DefiniGEN
3Dnamics Inc.
Organoid Therapeutics
InSphero
AIVITA Biomedical
JangoBio
Segment by Type
Tissue Derived Organoids
Pluripotent Stem Cell-derived Organoids
Segment by Application
Biopharmaceutical Companies
Contract Research Organizations
Academics and Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Organoid Biobank report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source